Background and objectives Serum phosphorus levels are associated with mortality, cardiovascular disease, and renal function loss in individuals with and without chronic kidney disease. The association of pretransplant serum phosphorus levels with transplant outcomes is not clear. Design, setting, participants, & measurements Data of the Scientific Registry of Transplant Recipients (SRTR) up to June 2007 were linked to the database (2001 through 2006) of one of the U.S.-based large dialysis organizations (DaVita)
Introduction
Serum levels of phosphorus are associated with mortality (1, 2) , cardiovascular disease (CVD) (3), and renal function loss in chronic kidney disease (CKD) patients (4 -6) . Both low and high serum phosphorus levels are associated with an increased risk of death (7, 8) , whereas risks of a cardiovascular event and kidney dysfunction increase linearly with serum phosphorus levels (4, 7) . In CKD patients on dialysis (dialysis-CKD), phosphorus levels over 6.5 to 7.0 mg/dl are significantly associated with increased mortality (1, 9, 10) , and therapeutic guidelines recommend maintaining serum phosphorus in the 3.5 to 5.5 mg/dl range (11) . Despite this, 50 to 60% of the U.S. dialysis-CKD patients who are potential kidney transplant candidates have serum phosphorus over 5.5 mg/dl.
The reasons for an inferior survival among low and high phosphorus dialysis-CKD patients are different. Hypophosphatemia, in the majority of the cases, is a marker of a poor nutritional status, whereas hyperphosphatemia can induce vascular calcification. High phosphorus levels can stimulate differentiation of vascular smooth muscle cells into osteoblastic-like cells, with bone matrix production and mineralization (12, 13) . As a consequence of stiffer arteries, pulse wave velocity, arterial sheer stress, and cardiac output resistance increase and may cause vascular intima damage and left ventricular hypertrophy (14 -16) . Coronary artery calcification may also contribute to coronary insufficiency and myocardial ischemia (17) . Therefore, hyperphosphatemia is considered a nontraditional risk factor for CVD in CKD patients, and for many kidney recipients vascular disease is an undesired heritage from the dialysis period (18, 19) .
Increased phosphorus wasting and hypophosphatemia are described in the posttransplant period (20, 21) . In native kidneys phosphaturia can cause calcium-phosphorus deposition in the tubules, which may trigger a local inflammatory response and lead to tubular obstruction, and ultimately to kidney failure (22) . These mechanisms may be reproducible in the renal allograft and may contribute to graft dysfunction (23) .
The effect of pretransplant recipients' serum phosphorus level on transplant outcomes is un-clear; however, a recent study showed in living kidney donor transplants that a higher donor phosphorus level was an independent risk factor for early allograft dysfunction (24) . We sought to examine the association of pretransplant serum phosphorus levels with all-cause and CVD mortality, graft failure, and delayed graft function (DGF) in a U.S.-based renal transplant population and we hypothesized that higher phosphorus levels are incrementally associated with poor graft and patient outcomes.
Materials and Methods

Patients
We linked data on all kidney transplant recipients listed in the Scientific Registry of Transplant Recipients (SRTR) up to June 2007 to a list of individuals with CKD who underwent maintenance hemodialysis treatment from July 2001 to June 2006 in one of the outpatient dialysis facilities of a U.S.-based large dialysis organization (DaVita Inc., before its acquisition of former Gambro dialysis facilities) using patients' social security numbers. The study was approved by the Institutional Review Boards of both Los Angeles Biomedical Research Institute at Harbor-UCLA and DaVita Clinical Research.
Clinical and Demographic Measures
The creation of the national DaVita dialysis patient cohort has been described previously (25) (26) (27) (28) (29) (30) (31) . To minimize measurement variability, all repeated measures for each patient during any given calendar quarter (i.e., over a 13-week interval) were averaged and the summary estimate was used in all models. Average values were obtained from up to 20 calendar quarters (q1 through q20) for each laboratory and clinical measure for each patient for up to 6 years of follow-up. The first (baseline) studied quarter for each patient was the calendar quarter in which the patient's dialysis vintage was Ͼ90 days. Demographic data and details of medical history were collected, with information on age, gender, race, type of insurance, marital status, presence of diabetes, height, posthemodialysis dry weight (to calculate averaged body mass index [BMI]), and dialysis vintage. Dialysis vintage was defined as the duration of time between the first day of dialysis treatment and the day of kidney transplantation.
Laboratory Measures
Blood samples were drawn using uniform techniques in all of the DaVita dialysis clinics and were transported to the DaVita Laboratory in Deland, Florida, typically within 24 hours. All laboratory values were measured by automated and standardized methods in the DaVita Laboratory. Most laboratory values were measured monthly, including serum urea, creatinine, albumin, calcium, phosphorus, bicarbonate, and total iron binding capacity (TIBC). Serum ferritin and intact parathyroid hormone (PTH) were measured at least quarterly. Hemoglobin was measured at least monthly in essentially all patients and weekly to biweekly in most patients. Most blood samples were collected predialysis with the exception of postdialysis serum urea nitrogen to calculate urea kinetics. Kt/V (single pool) was calculated using urea kinetic modeling equations as described elsewhere (27) . To ex-amine the "dose-response" association between pretransplant serum phosphorus categories and outcomes risk, we divided patients into five a priori defined categories based on pretransplant serum phosphorus level: Ͻ3.5, 3.5 to Ͻ5.5, 5.5 to Ͻ7.5, 7.5 to Ͻ9.5, and Ն9.5 mg/dl values.
Statistical Analyses
Data were summarized using proportions, means (ϮSD). We examined P values for trends across pretransplant serum phosphorus categories. Time-to-event survival analyses were done to determine association of serum phosphorus with all-cause and cardiovascular mortality and graft failure (defined as reinitiation of dialysis treatment or retransplantation). For delayed graft function (DGF), defined as the need for any dialysis therapy in the first week after transplantation (32) , time to event was not accounted for. Survival analyses to calculate hazard ratios (HRs) and 95% confidence intervals (95% CIs) of death or graft failure employed Cox proportional hazards regression. In mortality analyses patients were followed until event (death) or censoring (graft failure or end of follow-up period), whichever happened first. In graft failure analyses patients were followed until event (graft failure) or censoring (death or end of follow-up period), whichever happened first. In the combined outcome analyses patients were followed until event (death or graft failure) or censoring (end of follow-up period), whichever happened first. Proportional hazard assumption was tested using log(Ϫlog) against survival plots. Logistic regression models were used to estimate the odds ratio (OR) and 95% CI of posttransplant DGF.
For each regression analysis, four levels of multivariate adjustment were examined: (1) an unadjusted model that included pretransplant serum phosphorus categories (3.5 to Ͻ5.5 mg/dl as reference) as the predictor; (2) case-mix adjusted models that included the above plus age, gender, recipient race-ethnicity (African Americans and other selfcategorized blacks, non-Hispanic whites, Asians, Hispanics, and others), diabetes mellitus, dialysis vintage (Ͻ6 months, 6 months to 2 years, 2 to Ͻ5 years, and Ն5 years), primary insurance (Medicare, Medicaid, private, and others), marital status (married, single, divorced, widowed, and other or unknown), standardized mortality ratio of the dialysis clinic during entry quarter, dialysis dose as indicated by Kt/V (single pool), presence or absence of a hemodialysis catheter, and residual renal function during the entry quarter and eight comorbidities (atherosclerotic heart disease, congestive heart failure, cancer, chronic obstructive pulmonary disease, CVD, hypertension, peripheral vascular disease, and tobacco use); (3) malnutritioninflammation-complex syndrome (MICS) adjusted models which included all of the above covariates plus nine surrogates of nutritional status and inflammation measured during the last calendar quarter before transplantation including BMI and eight laboratory variables (i.e., normalized PCR [nPCR] as an indicator of daily protein intake, also known as the normalized protein nitrogen appearance [nPNA] [33] , and serum or blood concentrations of TIBC, ferritin, calcium, bicarbonate, peripheral white blood cell count, lymphocyte percentage, and albumin); and (4) casemix, MICS, and transplant data adjusted models included all of the above plus eight transplant-related variables: (1) donor type (deceased or living), (2) donor age, (3) donor gender, (4) panel reactive antibody (PRA) titer (last value before transplant), (5) number of HLA mismatches, (6) cold ischemia time, (7) DGF (except when DGF was a dependent variable in logistic regression models), and (8) extended donor criteria using standard definition (donor history of hypertension and/or serum creatinine of donor Ͼ1.5 mg/dl and/or cause of death in donor is cerebrovascular event). All analyses were carried out with SAS version 9.1 (SAS Institute Inc., Cary, NC) and STATA version 11.1 (STATA Corporation, College Station, TX).
Results
The original 5-year (July 2001 through June 2006) national database of all DaVita patients included 164,789 adult patients. Out of 65,386 DaVita patients who were identified in the SRTR database, 17,629 had undergone one or more kidney transplantations during their lifetime, but only 14,508 dialysis patients had undergone kidney transplantation for the first time. From these 14,508 dialyzed patients we excluded patients on chronic peritoneal dialysis (n ϭ 2092) and patients who did not have serum phosphorus measurements (n ϭ 3032). The analytic cohort consisted of the remaining 9384 patients who underwent first kidney transplantation during the observation period and who were followed until death, graft failure, loss of followup, or survival until June 30, 2007 (Supplemental Figure  S1 ). There were 737 deaths (7.9%) and 811 graft failures (8.6%) irrespective of subsequent deaths. The median cohort time was 803 days (interquartile range was 384 to 1330 days). The basic characteristics of waitlisted, but nontransplanted, patients have been described elsewhere (34) . Tables 1 and 2 show the clinical, demographic, and laboratory data of the 9384 transplanted patients across five pretransplant serum phosphorus categories.
The crude all-cause mortality rate was 32.3/1000 patientyears (95% CI: 30.1 to 34.8). The associations of pretransplant phosphorus categories with the posttransplant risk of death, cardiovascular death, graft failure, or the composite of graft failure or death and delayed graft function are shown in Table 3 . Compared with recipients with pretransplant phosphorus 3.5 to Ͻ5.5 mg/dl, recipients with pretransplant phosphorus of Ͻ3.5 and Ն9.5 mg/dl phosphorus had 66% (HR: 1.66, 95% CI: 1.18 to 2.33) and 32% (HR: 1.32, 95% CI: 0.85 to 2.03) higher all-cause mortality; and recipients with pretransplant phosphorus of 7.5 to Ͻ9.5 had 27% (HR: 0.73, 95% CI: 0.57 to 0.93) lower unadjusted death risk. After additional adjustment for case-mix and MICS and transplant-related variables, recipients with pretransplant phosphorus of Ն9.5 mg/dl phosphorus had 2.4-fold (HR: 2.44, 95% CI: 1.28 to 4.65) higher death risk compared with recipients with pretransplant phosphorus 3.5 to Ͻ5.5 mg/dl (Table 3A) . Figures 1, 2, 3 , and 4 show the cubic spline models for the association of the entire range of pretransplant serum phosphorus level with posttransplant outcomes. The association of pretransplant serum phosphorus level ( Figure 1 ) with all-cause mortality was U-shaped; both very low and very high phosphorus levels were associated with higher mortality risk. How-ever, in the low range the association was not statistically significant. A similar association pattern was found for cardiovascular death (Figure 2 ). After adjustment for casemix and MICS and transplant-related variables recipients with pretransplant phosphorus levels of Ն9.5 mg/dl had 3.6-fold (HR: 3.63, 95% CI: 1.13 to 11.64) higher cardiovascular death risk compared with recipients with pretransplant phosphorus 3.5 to Ͻ5.5 mg/dl (Table 3B ).
The crude graft loss rate was 35.6/1000 patient-years (95% CI: 33.2 to 38.1). Pretransplant phosphorus levels and graft loss risk ( Figure 3 ) became more closely associated starting at the level of 5 mg/dl and continuing up to extremely high levels. In our fully adjusted model, recipients with pretransplant phosphorus levels of 7.5 to Ͼ9.5 and Ն9.5 mg/dl phosphorus had 1.4-fold (HR: 1.42, 95% CI: 1.04 to 1.95) and 2.4-fold (HR: 2.36, 95% CI: 1.33 to 4.17) higher risk of graft loss compared with recipients with pretransplant phosphorus 3.5 to Ͻ5.5 mg/dl (Table 3C ). The association of pretransplant serum phosphorus level ( Figure 4 ) with the combined outcome was U-shaped. Both very low and very high phosphorus levels were associated with higher mortality risk; however, in the low range the association was not statistically significant.
We did not find significant associations between pretransplant phosphorus level and delayed graft function (Table 3E ).
Discussion
In this retrospective analysis of 9384 primary kidney transplant recipients we describe an association between pretransplant serum phosphorus levels higher than 7.5 and 9.5 mg/dl with an increased risk of death-censored graft failure and death, respectively.
Our findings are noteworthy for a number of reasons. First, the association of phosphorus levels with all-cause mortality and with cardiovascular mortality was not entirely comparable to findings in dialysis-CKD patients. Pretransplant serum phosphorus was only significantly associated with mortality in renal transplant recipients at very high levels (Ͼ9.5 mg/dl), whereas in dialysis-CKD patients this association has been demonstrated at relatively lower phosphorus levels (Ͼ6.5 or 7.0 mg/dl) (1, 10) . This difference may in part be explained by the transplant selection process. Only the healthiest recipients among those with multiple dialysis-related complications, including severe hyperphosphatemia are eligible to receive a transplant. As an example, in our study, recipients in the 7.5 to Ͻ9.5 and Ͼ9.5 group were younger and had fewer cases of diabetes mellitus, and fewer pretransplant comorbidities when compared with the other groups. Moreover, the higher phosphorus levels in our population may represent a better nutritional status. When comparing baseline characteristics, those in the 7.5 to Ͻ9.5 and Ͼ9.5 mg/dl group had higher BMI (with fewer recipients with diabetes mellitus), higher nPCR, higher creatinine, and similar serum albumin compared with the other groups. These characteristics may have attenuated the association of moderately increased phosphorus levels with mortality.
Hypophosphatemia (Ͻ3.5 mg/dl) was associated with mortality in the unadjusted and case-mix models, but not in the fully adjusted model (case-mix, MICS, and trans-plant characteristics). However, this last model examined outcomes of fewer recipients, which could result in loss of statistical power, and hence small associations may not have been identified. Therefore, it is hard to assume that phosphorus Ͻ3.5 mg/dl is not associated with mortality based only on the fully adjusted model results, as cubic spline curves showed a crescent risk of death with decrease of phosphorus to this level. However, in this low range the association was not statistically significant. This particular group of recipients should be further analyzed.
A second noteworthy finding was the association of phosphorus levels Ͼ7.5 mg/dl with death censored graft failure, while not showing associations with mortality. It seems that relatively lower levels of pretransplant phosphorus may be more closely associated with graft function than with survival. In the majority of kidney transplant recipients both serum phosphorus and PTH are expected to normalize after transplant, abrogating the effect of phosphorus as a vascular toxin. This does not immediately correct pre-established vascular lesions, although some cal- cified lesions may be gradually reabsorbed after successful transplantation (35) . As a result, it is possible that the mortality risk in those with moderate increases in serum phosphorus (Ͼ7.5 to 9.0 mg/dl) may be reduced after transplant. Elevated pretransplant phosphorus levels may represent the presence of large phosphorus reserves in the bones, which will usually be mobilized after transplanta-tion. Increased renal phosphorus wasting with associated hyphosphatemia is often observed after transplantation (21) . This is related to side effects of immunosuppressive drugs (calcineurin inhibitors [36] , sirolimus [37] , and steroids [20] ) and to increased levels of PTH and fibroblast growth factor 23 (FGF-23) that persist at least in the first few months after transplantation (38) . The presence of higher phosphorus concentrations in the tubules may lead to deposition of calcium-phosphorus crystals in the tubular epithelium, and contribute to the risk of graft failure (23) .
Molecules that facilitate crystal adhesion may be expressed in transplant tubular cells (22) , which may potentiate crystal deposition in the allograft. The crystal deposition may create a focus of inflammation that may progress to fibrosis and nephron loss (39) . Calcium oxalate, uric acid, and to a lesser extent calcium-phosphorus crystals increase production of monocyte-chemoattractant protein-1 and many other profibrotic and proinflammatory pathways (39, 40) . Therefore, a plausible hypothesis is that crystal deposition may contribute to graft loss either by triggering rejection episodes or by facilitating fibrosis. The mechanism of increased graft loss in recipients with higher pretransplant phosphorus seems not to involve delayed graft function. In our population associations with DGF could be mitigated by the higher frequency of living donor transplants in the Ͼ9.5 mg/dl group. However, we examined the risk of DGF separately in living and deceased donor recipients and we did not find a significant association (data not shown).
Two previous studies examined the relationship of pretransplant abnormalities in serum phosphorus, calcium, and PTH levels with transplant outcomes. Roodnat et al. (41) reported an association of elevated PTH but not phosphorus with increased graft failure, and Calabia et al. (42) showed that pretransplant calcium, PTH, and phosphorus levels were not associated with DGF. Other studies reported associations of serum phosphorus concentration during the transplant follow-up period with outcomes. Schaeffner et al. (43) reported that higher phosphorus or calcium-phosphorus product levels during the transplant follow-up period were associated with increased risk of graft dysfunction. Connolly et al. (44) and Stevens et al. (45) showed that posttransplant hyperphosphatemia was associated with increased mortality. Interestingly, in pediatric and adult populations, elevated FGF-23 levels during the transplant follow-up period were associated with increased risk for deterioration of kidney function and mortality, more so than phosphorus or PTH levels (46, 47) . Also, in pediatric recipients increased FGF-23 was associated with a higher number of rejection episodes (46) .
Our study has several limitations related to its retrospective nature. Data on induction and maintenance immunosuppression, cardiovascular medications (statins, ␤-blockers, etc.), and coronary artery calcification were not available. Pretransplant use of phosphorus binders and other dietary treatments (48 -51), vitamin D analogs, or calcimimetics was not taken into consideration, and it is Model adjusted for age, gender, recipient race-ethnicity, diabetes mellitus, dialysis vintage, primary insurance, marital status, standardized mortality ratio of the dialysis clinic during entry quarter, dialysis dose as indicated by Kt/V (single pool), presence or absence of a hemodialysis catheter, and residual renal function during the entry quarter, eight comorbidities, body mass index, nPNA, serum or blood concentrations of TIBC, ferritin, calcium, bicarbonate, peripheral white blood cell count, lymphocyte percentage, albumin, donor type, donor age, donor gender, panel reactive antibody titer (last value before transplant), number of HLA mismatches, cold ischemia time, DGF, and extended donor criteria. Abbreviations: DGF, delayed graft function; nPNA, normalized protein nitrogen appearance; TIBC, total iron binding capacity.
possible that recipients with similar phosphorus levels have different degrees of severity of metabolic bone disease, and therefore different levels of vascular damage. PTH levels were also not examined in conjunction with phosphorus levels, as data on this were missing in the majority of the patients. Moreover, uneven distribution of serum phosphate measurement frequency in the study sample (some may have more measurements than others) might also result in bias.
Conclusions
Individuals with pretransplant phosphorus levels Ͼ7.5 mg/dl have increased risk of functional graft failure and those with levels over 9.5 mg/dl are also at increased risk for all-cause and cardiovascular mortality. Recommendations to keep phosphorus levels between 3.5 and 5.5 mg/dl during the dialysis period are important not only to reduce dialysis-related mortality but also possibly for the success of kidney transplantation.
